Cellectis | GenomeWeb

Cellectis

CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.

The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.

Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.

The firm adds CRISPR/Cas9 gene editing to its portfolio of plant genome engineering technologies, which also includes meganucleases and TALENs.

Based in New York, the subsidiary will feature laboratory space to develop the firm's chimeric antigen receptor T cells for cancer immunotherapy.

The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq. 

The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.

NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.

Pages

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.